-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, HUTCHMED Announces Phase III ESLIM-02 Trial Success For Sovleplenib Expanding Immunology And Hematology Pipeline

Benzinga·01/07/2026 06:45:14
语音播报

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —